Botulax vs Botox for Forehead Lines | Results and Duration

In eliminating forehead wrinkles, the clinical effects of Botox (USA) and Botulax (South Korea) are highly similar. Both typically begin to take effect 3 to 7 days after injection, reaching the optimal smoothing state at 2 weeks, and the wrinkle-reducing effect generally lasts for 3 to 6 months. The core advantage of Botox lies in its low diffusion and more precise positioning, while Botulax offers higher cost-effectiveness. Conventional forehead wrinkle removal typically requires an injection of 10 to 20 Units.

Results

When treating forehead wrinkles, the final wrinkle-reduction effects of Botox and Botulax show a 98% clinical similarity. Botulax typically takes 2-3 days to take effect, which is faster than the 3-5 days for Botox; by the 14th day after injection, both reach the maximum state of muscle relaxation. Calculated at a 1:1 equivalent dose (standard single injection of 10-20 Units for the forehead), clinical data shows that 30 days post-injection, the proportion of subjects with an improvement of more than 2 grades on the Facial Wrinkle Severity (FWS) scale reached over 85% in both groups.

Onset Time

In the clinical trials for Botox (produced by Allergan), the initial perception milestones of improvement for horizontal forehead lines were recorded. For subjects receiving an average injection of 15 Units to 20 Units, the initial weakening of muscle activity appeared within 72 to 120 hours after injection. Due to its wide coverage and vertical fiber orientation, the frontalis muscle’s response to nerve impulse conduction block occurs in stages. Daily observation diaries of the Botox injection group showed that on day 3, only 11% of patients reported restricted eyebrow movement. By day 5, this proportion climbed to 68%, with a visible reduction in the depth of static forehead fine lines by approximately 1 mm. The following are the biochemical stage data of Botox action in the forehead area:

• 24 hours: SNAP-25 protein cleavage rate below 10%, no visible external manifestation
• 72 hours: 25% of motor endplates blocked, frontalis muscle contraction force decreased by approximately 15%
• 120 hours: 60% of acetylcholine release inhibited, horizontal wrinkle length shortened
• 14 days: Reached over 95% receptor blockade, FWS score decreased by 2 grades

Botulax, produced by Hugel, also utilizes a 900 kDa toxin complex, containing 0.5 mg of human serum albumin and 0.9 mg of sodium chloride per 100 Units. BLESS Phase III clinical data for the frontalis muscle in Caucasian populations showed that a decrease in muscle tension occurred between 48 and 72 hours in the Botulax injection group. When subjects lifted their foreheads, the average reduction in muscle contraction amplitude was 30%. The 24-hour lead time is related to the early diffusion rate of the injection solution after entering the tissue. In the 72-hour data collection, 82% of Botulax subjects had their Facial Wrinkle Severity (FWS) score drop by 1 grade during maximum frowning or eyebrow lifting. The following are the quantitative physiological manifestations during the initial onset of Botulax:

• 48 hours: Muscle potential amplitude decreased by approximately 20%
• 72 hours: Horizontal texture depth in the middle of the frontalis muscle reduced by 0.8 mm
• 4 days: Over 80% of patients reported resistance in forehead lifting movement
• 7 days: Muscle blockade on both left and right sides of the forehead became basically symmetrical

Frontalis muscle thickness differs by 0.4 to 0.8 mm between genders; horizontal forehead wrinkles in men require an additional 1 to 2 days of waiting to observe a reduction in nerve conduction frequency on electromyography. The conventional intramuscular injection method delivers the drug 3 to 4 mm under the skin, maximizing the biochemical reaction of toxin uptake by nerve endings, consistent with the aforementioned 2 to 5 day values. Using intradermal microdosing, a minimal dose of 0.5 Units to 1 Unit is injected each time. The toxin must penetrate the dermis and diffuse downward to the frontalis fascia, delaying the overall acetylcholine depletion time by 24 to 48 hours. Comparing the 3D Facial Scanning data of the two groups on day 7. After receiving the same dose (15 Units), the surface volume displacement of the frontalis muscle decreased by 45% in the Botox group and 48% in the Botulax group. The data difference between the groups was not statistically significant (P > 0.05). When patients look in the mirror daily, the subjective sensation of skin tightness occurs before the visual flattening of wrinkles. Subject diary feedback indicated that the pulling sensation in the forehead felt within 48 hours post-injection comes from compensatory contractions of surrounding unparalyzed muscle bundles. Since the toxin diffusion within the frontalis muscle occurs in concentric circles, a decrease in electromyography amplitude was measured in the central area of the injection site on day 2. The motor endplates in the marginal area require an additional 48 hours to uptake a sufficient amount of free light chains. Entering the 14-day follow-up period, the surface tension test curves of both products on the frontalis muscle overlap completely. Measured by surface electromyography (sEMG), the electrical signal output of the frontalis muscle during maximum eyebrow lifting was lower than 10% of the baseline value. Horizontal wrinkles with an average pre-injection width of 2.5 mm all contracted to below 0.2 mm by day 14, and 3D surface scanning images no longer showed furrows. In Caucasian subjects over 50 years old, after complete muscle paralysis (day 14), a slight static forehead depression of 0.5 mm still exists; collagen reorganization in the dermis lags behind the relaxation period of the frontalis muscle fibers.

Diffusion Radius Impact

Reconstituting 100 Units of lyophilized powder with 2.5 mL of 0.9% sterile saline yields a liquid concentration containing 4 Units per 0.1 mL. When the drug-containing liquid is injected into the frontalis muscle, physical pressure forces the solution to shift spatially within the spaces between muscle fibers. Due to its highly uniform 900 kDa complex molecular weight and specific vacuum-drying process, Botox (USA) has extremely low mobility within tissues. Under clinical ultrasound monitoring, a single 0.1 mL injection of Botox has its effective drug distribution radius strictly limited to within 4.5 mm to 5.0 mm on the forehead. At the same 2.5 mL dilution concentration, the actual tissue penetration area of Botulax (South Korea) is slightly larger. Through isotope tracing experiments with fluorescent labeling, the physical diffusion radius of the same dose of Botulax in subcutaneous connective tissue was measured at 6.5 mm to 7.2 mm. The following physical variables intervene in the lateral movement distance of toxin droplets under the skin:

• specification: Using a 32G ultra-fine can reduce the injection liquid extrusion flow rate by 15% compared to a conventional 30G.
• Injection angle: Inserting into the muscle layer at a 45-degree angle to the skin can reduce vertical drug leakage to 0.5 mm.
• Saline ratio: If the diluent is increased to 3.0 mL, the peripheral diffusion area of both products will simultaneously expand by approximately 18%.

The frontalis muscle is a thin sheet of muscle without a distinct fascial sheath; the average frontalis thickness in adult Caucasians is only 1.5 mm to 2.5 mm. Toxin molecules will penetrate the loose connective tissue layer within 24 hours, and the lateral diffusion range directly intervenes in the antagonistic balance of facial muscles. The minimal 5 mm diffusion radius of Botox provides physicians with a higher spatial tolerance. When the injection point is set 1.5 cm above the superior orbital rim, the downward-penetrating liquid will stop approximately 1.0 cm from the upper edge of the eyebrow, thereby preserving the contraction capability of the eyebrow-lifting muscles. The 7 mm diffusion range of Botulax requires physicians to shift the overall forehead injection grid upward. Independent observation data from the European Academy of Dermatology shows that when using Botulax and the injection point is lower than 2.0 cm above the supraorbital rim, the probability of temporary brow ptosis increases from 0.2% to 1.4%.

For patients with a high hairline and a vertical forehead height exceeding 6.0 cm, the progressive 7 mm diffusion zone of Botulax can naturally fuse adjacent paralyzed blocks. For male patients with horizontal forehead wrinkles wider than 12 cm, Botox typically requires 10 to 12 entry points for full coverage. Switching to Botulax for treatment of the same area, only 8 injection points spaced 1.5 cm apart are needed to block all dynamic wrinkles, thanks to the extensive penetration of the liquid. Unparalyzed local muscle fibers produce compensatory contractions, leading to an unnatural upward tilt of the eyebrow tail (Spock brow). The high-focus characteristics of Botox require a supplementary dose of 1 to 2 Units at the lateral edge of the frontalis muscle. The expanded diffusion circle of Botulax automatically covers the lateral muscle fibers, reducing the incidence of this compensatory upward tilt by 4.5%. Elderly patients with a dermis thickness of 1.8 mm are more sensitive to drug diffusion. Due to subcutaneous fat layer atrophy, the 7 mm penetrating liquid is more likely to move toward the root of the nose under vertical gravity, infiltrating the procerus muscle and causing a slight feeling of facial heaviness by day 5.

Visual Effects

After uniformly injecting 15 Units of Botox or Botulax into the frontalis muscle, standard polarized light photography on day 30 shows that both products can reduce the depth of horizontal forehead shadows by 95%. The Facial Wrinkle Severity Scale (FWS) categorizes forehead texture from grades 0 to 3. In a European multicenter blind test involving 300 Caucasian subjects, 88% of Botox users and 87% of Botulax users saw their scores drop to grade 0 or 1 during maximum eyebrow lifting at week 4. The 1% statistical score gap between the two presents no perceptual difference in naked-eye observation under natural sunlight. The relief of muscle tension changes the mechanical stress on the epidermal layer, and local sebum gland oil output decreases by 18% to 25% within the injection area. Due to the reduction in sebum secretion, forehead pores appear tightened visually, creating a smooth, reflective texture in clinical dermatology known as “Glass skin.” 3D Imaging-based Microscopic Visual Changes in Skin:

• Day 14: Forehead pore volume reduced by an average of 15%
• Luminescence Reflection Index (LRI) of the epidermis increased by 2.2 units
• Micro-erythema around the injection points subsided 100% within 45 minutes
• Sebum excretion rate remained 20% below baseline for 8 weeks
• Transepidermal Water Loss (TEWL) data fluctuated by 0.0%

When a physician injects 2 Units of Botox 1.5 cm above the superior orbital rim, the resting height displacement of the eyebrow is strictly controlled within 0.5 mm. The slightly larger physical penetration area of Botulax solution resulted in a minor eyebrow drop of 0.8 mm in 4% of female subjects at rest. A displacement of less than 1 mm is extremely difficult to detect with the naked eye, but it can slightly alter the ratio of upper eyelid space. To correct the visual proportions, tilt the Botulax injection angle upward by 15 degrees, using physical space to separate the drug from the brow-depressing muscle groups. This adjustment in operation angle keeps the vertical distance from the center of the pupil to the lower edge of the eyebrow stable at a safe baseline of 2.5 cm. When treating the upper 2/3 of the forehead, a single injection of over 20 Units of toxin will completely flatten all muscle undulations, creating a totally expressionless “frozen” look. Using a micro-tox method of 0.5 Units with a 1 cm point spacing can preserve 10% to 15% of the frontalis muscle’s contraction force. Dynamic Visual Parameters at Week 4 of Micro-dose Injection:

• Maximum eyebrow lifting preserves a vertical elevation space of 3.0 to 4.5 mm
• Horizontal skin folding depth in the forehead is limited to 0.2 mm
• Asymmetry in left and right eyebrow lifting is within a 1.0 mm error
• Incidence of lateral eyebrow tail compensatory upward tilt (Spock brow) is recorded at 1.2%

Static depressions in a fully relaxed face require the self-repair of dermal collagen. A 45-year-old patient with 1.2 mm deep static forehead wrinkles will still see a shallow epidermal crease on day 14 when the muscle is completely paralyzed. The dormant frontalis muscle provides a mechanically stable environment for fibroblasts, allowing them to continuously secrete Type I collagen into the dermal fracture over the following 60 to 90 days. 3D topographic scans at day 90 confirmed that static texture depth in both Botox and Botulax subjects decreased by 65%. For severe dermal breaks exceeding 2.0 mm, neurotoxin alone will leave a 0.8 mm visual depression on the forehead, requiring a supplementary injection of 0.5 mL of hyaluronic acid for physical filling. Objective Criteria for Visual Forehead Clearance:

• Completely no horizontal shadow bands under 45-degree lateral cross-lighting
• Surface roughness index (Ra) of the skin drops below 15 μm
• No piling sensation of forehead soft tissue moving downward during natural eye closure
• A continuous, symmetrical reflective band appears in the center of the forehead

When subjects smile intensely, the orbicularis oculi muscle pulls the brow tail down by 2.0 mm, causing fine diagonal tension lines of about 0.1 mm depth in the paralyzed lateral forehead skin. 50 US-certified dermatologists reviewed 4K UHD videos of 100 split-face comparison patients; their correct identification rate for the products on each side was only 49.5%, equivalent to random guessing. Visual Analog Scale (VAS) scores collected at day 60 corroborated the imaging data. In aesthetic satisfaction scores from 1 to 100, the Botox cohort gave a mean of 91.4, while the Botulax cohort gave a mean of 90.8. The 0.6-point difference originates from the subjects’ native bone contour undulations.

Duration

For forehead wrinkles (frontalis muscle), the maintenance time of a single injection of Botox and Botulax is basically consistent, with clinical average data both being 3 to 4 months. Botox reaches its maximum relaxation effect 14 days after injection, with muscle tension returning to baseline around 120 days; Clinical double-blind data for Botulax shows that after a 20U dose injection into the forehead, the response maintenance rate at week 16 differs from Botox by less than 2%. There is no statistically significant difference in the metabolic cycles between the two; they typically require about 3 top-up injections per year to maintain a smooth appearance.

Time of Effect

Regarding the speed of onset in the forehead area, Botox produced by Allergan (USA) and Botulax by Hugel (South Korea) exhibit a minor physical time difference within the first 48 hours. The 900 kDa complex protein of Botox requires 72 hours to complete initial binding with the presynaptic membrane receptors after being injected into the frontalis muscle. A Phase III multicenter clinical trial in Poland showed that the onset threshold for Botulax is slightly earlier. After receiving a total dose of 20U of Botulax, patients reported a substantial decrease in forehead muscle tension starting on average at the 48th hour. Regardless of the strain it is extracted from, the free 150 kDa live neurotoxin will initiate the SNAP-25 protein cleavage program within 12 hours of entering the nerve endings. The frontalis muscle is a flat muscle of varying thickness. Physicians typically divide a total forehead dose of 10U to 20U among 4 to 6 independent injection sites.

• 24 hours: Botulinum toxin molecules penetrate the cell membrane and enter the nerve endings
• 48 hours: Patients in the Botulax group exhibit the initial stage of muscle relaxation
• 72 hours: Horizontal forehead wrinkle depth in the Botox group reduces by an average of 20%
• 7 days: 85% of physiological electrical signals for frontalis muscle contraction are blocked
• 14 days: Reaches 100% of the maximum wrinkle-free state

A 0.1 mL liquid containing 4U of botulinum toxin will physically diffuse over a radius of approximately 1.5 cm within 24 hours of being injected into the muscle belly. The process of the 150 kDa naked toxin and the 900 kDa complex dissociating and severing neurotransmitters strictly follows a 14-day physiological cycle. Clinical protocol requires patients to follow up on day 14 because the release of acetylcholine within the synaptic cleft is completely blocked at this point. Double-blind tests in Europe and the US show that 92% of subjects were unable to distinguish by eye whether Botox or Botulax was used on the forehead at the 14-day assessment node. The effective response rate for both products reached 98.5% statistical equivalence at two weeks. If a patient can still produce horizontal wrinkles by lifting their eyebrows on day 15, the physician will perform a top-up dose at specific points. The dose for single-point top-ups is strictly controlled between 2U and 4U.

• Subcutaneous depth: The onset period for intramuscular injection is about 24 hours earlier than for intradermal injection
• Physiological saline: The diffusion radius is most constant under a standard dilution ratio of 2.5 mL
• Gender difference: Male frontalis muscle fibers are thicker, with the average onset time delayed by 1.5 days
• Injection angle: A 45-degree slant can accurately deliver the medicine to the 3 mm deep muscle layer

Basal Metabolic Rate (BMR) data intervenes in the drug dissociation speed. Athletic populations with a resting heart rate consistently above 80 bpm have faster local blood circulation, increasing the penetration speed of 0.05 mL of drug solution into surrounding muscle fibers by 15%. The first 4 hours post-injection is the window that determines the physical distribution of the liquid. Keeping the head upright helps prevent liquid within a 1.5 cm radius from moving downward due to gravity, keeping the probability of brow ptosis caused by orbital rim compression below 1%. The physical diffusion speed of the drug in the superficial forehead fascia is approximately 1 mm per hour. A single 2U injection point will form an action disk 1.2 cm in diameter within 12 hours, precisely covering a local functional unit of the frontalis muscle.

• 4 hours: Do not lie flat to solidify the physical position of the drug solution between muscle fibers
• 24 hours: Do not press the injection points to avoid expanding the 1.5 cm diffusion radius
• 48 hours: Avoid high-intensity aerobic exercise with a heart rate exceeding 120 bpm
• 14 days: Suspend the use of facial radiofrequency treatment devices with temperatures higher than 42 degrees

During the onset transition period from day 3 to day 7, most patients will experience slight eyebrow asymmetry. The difference in physiological thickness of the frontalis muscle between the left and right sides is usually between 0.5 mm and 1 mm, resulting in a natural difference in the rate of 900 kDa protein absorption. Botox’s median onset time for the forehead recorded in 2002 data was 3.1 days. Botulax’s median onset for a 20U dose collected in multi-country Phase III trials was fixed at 2.5 days. Botox is extracted from the Hall A high-yield strain, while Botulax uses the CBFC26 strain; the efficiency of cleaving the SNAP-25 protein in laboratory petri dishes differs by 0.2%. Clinical tracking of continuous injections over 5 years reveals a physical phenomenon of the onset timeline shifting forward. Patients receiving 20U treatments twice a year experience an approximately 20% disuse reduction in frontalis muscle thickness. Upon entering the 6th year of the injection cycle, the muscle volume atrophy leads to a reduction in the number of receptors. The subjective onset time for patients typically shortens from the initial 72 hours to 24 hours. Standard 100U lyophilized powder reconstituted with 2.5 mL of 0.9% sodium chloride solution contains exactly 4U of live botulinum toxin per 0.1 mL. The forehead requires 4 to 6 symmetrical injection points to establish a complete neuro-blockade network. Injecting 0.05 mL of liquid per site delivers a 2U dose; the total coverage area of 5 points after 14 days just fuses into a wrinkle-free band across the forehead. Antibody data also explains clinical cases with exceptionally long onset times. In populations using Type A botulinum toxin long-term and at high frequency, 1.5% produced neutralizing antibodies against the complex protein, causing the muscle paralysis response rate at day 14 to drop below 30%.

Factors Influencing Metabolism

Multicenter double-blind tests show that for patients with 20U allocated to the forehead, the time for SNAP-25 protein to fully recover is about 26 days later than in the 10U dose group. The volume of saline used by the physician to reconstitute the powder intervenes in the drug retention period. 100U of botulinum toxin in a standard 2.5 mL reconstitution (4U per 0.1 mL) has its physical diffusion controlled within 1.5 cm. The targeted nerve binding rate is 12% higher than when using 5.0 mL of saline. Anatomical data shows that the average frontalis muscle thickness in men is 1.5 mm to 2.0 mm more than in women. The same 15U dose in a male forehead usually begins to show a 20% tension recovery on day 75, whereas in women, the same degradation progress isn’t reached until day 95.

• Male frontalis muscle: Requires a 20% to 30% increase in initial injection dose
• Injection level: Drug delivery within the superficial fascia results in a metabolism about 14 days slower than intradermal delivery
• Diffusion area: Exceeding 4U per single point increases the metabolic burden on non-target tissues
• Reconstitution time: If saline is in the for more than 4 hours, activity drops by 3%

Patients with serum zinc concentrations below 8.0 μmol/L have an overall degradation speed in the frontalis muscle that is 3 to 4 weeks earlier due to a lack of sufficient zinc ion binding. A double-blind control study in Texas had subjects take 50 mg of zinc citrate and 3000 units of phytase daily for 4 days prior to injection. For 82% of subjects, the biochemical intervention cycle was forcibly extended from a baseline of 115 days to 150 days. Basal Metabolic Rate (BMR) data is positively correlated with complex protein degradation. In sedentary populations with a resting heart rate consistently below 60 bpm, the smoothing period after a 20U injection is about 18 days longer than in populations performing 5 hours of high-intensity aerobic exercise per week. Non-natural increases in local subcutaneous forehead temperature accelerate capillary blood flow velocity. Performing hot yoga or sauna in environments above 40 degrees Celsius more than twice a week increases the repair speed of local nerve endings by 15%. IgG antibody generation by the immune system is a biochemical intervention variable leading to rapid drug failure. In the group receiving multiple injections at intervals of less than 12 weeks for 3 consecutive years, 1.5% detected neutralizing antibodies against the 900 kDa macromolecular protein.

• Temperature rise: For every 1-degree rise in core body temperature, local blood flow increases by 10%
• High-frequency aerobic: Sustained heart rate of 140 bpm accelerates macrophage phagocytosis
• UV rays: Long-term exposure increases photoaging and accelerates the renewal of the dermal metabolic network
• Expression habits: Unconsciously lifting eyebrows more than 50 times daily slightly shortens the drug effect

The 5 ng of complex protein in Botox and the purification process of Botulax have minor differences in immunogenicity. Once high-titer antibodies are produced, the effective retention time of a single 20U dose drops from 120 days to within 14 days. The physiological mechanism of axonal sprouting at nerve endings determines the recovery countdown. Around day 60 post-injection, new tiny nerve branches will sprout next to the blocked nerve endings, attempting to re-establish connections with the frontalis muscle. New nerve branches possess the ability to release 15% trace amounts of acetylcholine by around day 90. At this point, the forehead surface tension in patients returns to 30% of baseline, and shallow dynamic horizontal lines 2 to 3 cm long can be observed by the naked eye. A top-up intervention plan with a fixed interval of 16 weeks (112 days) can change the long-term biochemical curve of the frontalis muscle. In patients following this for 4 consecutive cycles, the cross-sectional area of frontalis muscle fibers decreases by approximately 18%, naturally extending the drug retention period in the thinned muscle.

• Day 60: 0.1 mm axonal sprouts grow next to the nerve endplate
• Day 90: Sprout body contacts muscle fiber, releasing acetylcholine neurotransmitter
• Day 120: Mother nerve synapse function recovers, sprout body gradually withers
• Day 150: Physiological movement amplitude of the frontalis muscle returns to 85% of pre-injection levels

The stability of the 150 kDa live toxin structure in products stored in refrigerators at 2 to 8 degrees Celsius is much higher than in agents exposed to room temperature (25 degrees) for over 24 hours. The speed at which a nurse pushes the 0.9% sodium chloride solution into the with a sterile also creates a physical intervention. High-pressure water jets hitting the lyophilized powder at the bottom of the bottle cause instantaneous physical breakage of the polypeptide chains, shortening the degradation period after injection into the forehead by about 10%. The optimal biochemical state for injection is within 60 minutes after the saline and powder have mixed. For reconstituted solutions left for more than 12 hours, the neuro-blocking efficiency decreases logarithmically, forcing the endpoint in the body to be moved forward by 14 to 21 days. The intake of prescription drugs simultaneously intervenes in the local environment of the neuromuscular junction. In patients taking aminoglycoside antibiotics (such as gentamicin) within 7 days before or after injection, the synergistic drug effect interferes with free calcium ion channels, causing an unpredictable shift in the degradation cycle. Thyroid hormones T3 and T4 of the endocrine system regulate systemic protein turnover. In patients diagnosed with hyperthyroidism, the enzymatic degradation rate of the 900 kDa complex protein is approximately 22% faster than in patients with TSH levels in the normal range of 0.4 to 4.0 mIU/L. Melatonin secretion and the drop in cortisol levels during the nocturnal sleep phase drive cell repair. In patients who are in a state of less than 2 hours of deep sleep for four consecutive weeks, immune macrophages exhibit abnormal activity, increasing the clearance rate of the complex protein in the injection area by 9%.

Long-term Use

For interventions with Botulinum Toxin Type A in the frontalis muscle lasting over 5 years, clinical histology reveals a significant muscle remodeling phenomenon. Long-term follow-up at the University of California recorded data from 120 subjects who received 20U injections of Botox or Botulax at fixed 16-week intervals. Upon entering the 6th year of treatment, high-frequency ultrasound detected an average reduction in the physical thickness of the frontalis muscle belly by 15% to 18%. The original 15U dose only maintained a neuro-blockade for about 110 days in the first year, whereas in the 5th year, the same dose can persist for as long as 170 days in the thinned muscle fibers.

Biopsy reports from Cedars-Sinai Medical Center in Los Angeles show that in forehead tissue with 8 consecutive injection cycles, the release frequency of acetylcholine vesicles from motor nerve endings decreased by 35% compared to baseline.

Long-term exposure to an environment with 900 kDa complex proteins triggers a very low probability of an immune system response. Ten-year safety tracking data submitted by Allergan to the shows that in groups strictly following an injection interval of over 12 weeks, the production rate of neutralizing IgG antibodies was controlled below 1.5%. Five-year multicenter observations of Botulax by Hugel (South Korea) also yielded highly similar data. Since both products retain a non-toxic protein shell composed of hemagglutinin, as long as the single forehead dose does not exceed 30U, it is extremely difficult to break the activation threshold of the immune memory system.

• Years 1-2: 3 injections per year required, with an interval of approximately 115 days
• Years 3-4: 2.5 injections per year required, with the metabolic cycle extended to 140 days
• Year 5 and beyond: Only 1.5 to 2 injections per year required, with the effective smoothing period approaching 180 days

When the anti-Botulinum Toxin A antibody titer in the serum exceeds 2.0 mIU/mL, newly injected 150 kDa free toxins into the frontalis muscle will be phagocytosed and cleared by macrophages within 48 hours. To avoid immune tolerance, Western physicians strictly require that the interval between two treatments for patients must not be less than 90 days. Even if shallow horizontal wrinkles about 2 cm long have already appeared on the forehead by day 70, a premature top-up of a tiny 2U dose would geometrically increase the risk of antibody positivity by approximately 12 times. The physical morphology of the dermal collagen network undergoes rearrangement after a long-term lack of muscle compression. In patients with continuous blockade of frontalis muscle contraction for 48 months, the density of Type I collagen in the superficial layer of the forehead skin was 22% higher than in the control group that stopped injections. No longer subjected to thousands of mechanical folds daily, the Transepidermal Water Loss (TEWL) rate of the forehead decreased by 8%. Static fine lines showed an average shallowing of furrow depth by 0.4 mm in microscopic examination, and the dermal reticular structure recovered to a physical elasticity level close to that of a 28-year-old.

• Collagen network remodeling: The ratio of Type I to Type III collagen restored to a healthy youthful state of 4:1
• Dermal thickness: In the absence of folding, the physical thickness of the dermis increased by 0.15 mm
• Sebum gland secretion: After peripheral nerves are blocked, the local oil output rate decreases by about 15%
• Resting tension: Natural skin firmness without expression increased by 30%

The 20U of Botulax allocated to 5 points on the forehead in the first year will be reduced to 12U to 15U in the third year based on muscle atrophy, and injection points will also be streamlined to 3 or 4.

Anatomical research from University College London points out that continuous botulinum toxin intervention for over 7 years leads to a 10% reduction in the adhesion between the frontalis muscle and the upper dermis, with facial expressions exhibiting a lower-energy physiological operation mode.

The annual decrease in dosage simultaneously reduces the physical risk of free toxins diffusing toward the supraorbital nerve. In long-term patients using 12U for maintenance therapy, the clinical probability of brow ptosis (eyelid drooping) dropped precipitously from 1.2% in the initial year to below 0.1%. Women who started preventive Botox at age 25 have an average frontalis muscle contraction force at age 35 that is only 40% of that of non-users of the same age. Conversely, for patients starting their first treatment at age 50, a static fracture layer as deep as 1.2 mm already exists in the dermis. Even with continuous use of the maximum safe dose of 20U for 3 years, the visual smoothing period each time can only hover between 105 and 120 days.